Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pramipexole ER versus placebo and pramipexole IR in levodopa-treated advanced Parkinson's disease
2007-000074-23Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pramipexole in Parkinson's disease (PD) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change from baseline to week 18 in UPDRS parts II and III total score. Started Mar 2007; status: completed.
02
Drugs
pramipexole
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2007-000074-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000074-23.